OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Daver on Azacitidine and Nivolumab in Acute Myeloid Leukemia

February 26th 2020

Naval G. Daver, MD, discusses the rationale of azacitidine and nivolumab in acute myeloid leukemia.

Dr. Blum on the Current Treatment Landscape of Acute Myeloid Leukemia

February 26th 2020

William G. Blum, MD, discusses the current treatment landscape of acute myeloid leukemia.

Dr. Penson on the Eligibility Criteria for PARP Inhibitors in Advanced Ovarian Cancer

February 26th 2020

Richard T. Penson, MD, MRCP, associate professor of medicine, Harvard Medical School, and clinical director of Medical Gynecologic Oncology, in the Department of Medicine, Massachusetts General Hospital, discusses the eligibility criteria for PARP inhibitors in advanced ovarian cancer.

Dr. Hoffman on Research Regarding Neoadjuvant Chemo and Primary Debulking in Ovarian Cancer

February 26th 2020

Mitchel Hoffman, MD, gynecologic oncologist, Moffitt Cancer Center, discusses ongoing research regarding neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian cancer.

Dr. Wenham on Trials Evaluating IP, IV, and Dose-Dense Chemotherapy in Ovarian Cancer

February 26th 2020

Robert M. Wenham, MD, gynecologic oncologist and chair of the Gynecologic Oncology Program at Moffitt Cancer Center, discusses data with intraperitoneal (IP) chemotherapy, dose-dense chemotherapy, and intravenous (IV) chemotherapy in patients with advanced ovarian cancer.

Dr. Beltran on Use of ctDNA to Evaluate Treatment Resistance in Prostate Cancer

February 25th 2020

Himisha Beltran, MD, associate professor of medicine, Lank Center for Genitourinary Oncology, Division of Molecular and Cellular Oncology, Harvard Medical School, director of Translational Research, and physician, Dana-Farber Cancer Institute, discusses the potential use of circulating tumor DNA to detect castration-resistant neuroendocrine prostate cancer.

Dr. Gerds on Luspatercept to Treat Anemia in Myelofibrosis

February 25th 2020

Aaron Gerds, MD, discusses results of a phase II trial examining the safety and efficacy of luspatercept as a treatment for anemia in patients with myelofibrosis.

Dr. Mesa on the Safety Profiles of JAK Inhibitors in Myelofibrosis

February 25th 2020

Ruben Mesa, MD, discusses the adverse events of ruxolitinib and fedratinib in myelofibrosis.

Dr. Jain on Challenges With Allogeneic Transplant in Myelofibrosis

February 25th 2020

Tania Jain, MBBS, discusses the challenges with allogeneic transplant in patients with myelofibrosis.

Dr. Copeland on the Prevalence of Ovarian Cancer in the United States

February 25th 2020

Larry J. Copeland, MD, discusses the prevalence of ovarian cancer in the United States.

Dr. Morris on Treatment Advances Made in BRAF-Mutated mCRC

February 25th 2020

Van K. Morris, MD, discusses the recent progress made in the treatment of patients with BRAF-mutated metastatic colorectal cancer.

Dr. Vusirikala on Hyper-CVAD Plus Ponatinib in Philadelphia Chromosome-Positive ALL

February 25th 2020

Madhuri Vusirikala, MD, discusses the benefit of hyper-CVAD and ponatinib in patients with Philadelphia chromosome–positive ALL.

Dr. Comerci on the Utility of Primary Debulking Surgery in Ovarian Cancer

February 25th 2020

John T. Comerci, MD, discusses the utility of primary debulking surgery in ovarian cancer.

Dr. Tagawa on Preliminary Data With 225Ac-J591 in mCRPC

February 25th 2020

Scott T. Tagawa, MD, MS, discusses preliminary data with 225Ac-J591 in metastatic castration-resistant prostate cancer.

Dr. Hamid on a Potential Biomarker of Response to Docetaxel in mHSPC

February 25th 2020

Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the potential predictive value of the luminal B subtype as a biomarker of response to docetaxel in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).

Dr. Armstrong on AR-V7 as a Biomarker of Response to Taxane Chemotherapy in mCRPC

February 25th 2020

Andrew J. Armstrong, MD, professor of medicine, associate professor in pharmacology and cancer biology, and professor in surgery at Duke University School of Medicine and a member of the Duke Cancer Institute, discusses the potential of AR-V7 as a predictive biomarker of response to taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Levy on the Current State of Liquid Biopsies Across Tumor Types

February 22nd 2020

Benjamin P. Levy, MD, assistant professor of oncology and clinical director of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the current state of liquid biopsies across tumor types.

Dr. Lazarides on CRM1 as a Potential Target in Osteosarcoma

February 22nd 2020

Alexander Leandros Lazarides, MD, resident at Duke University Medical Center, discusses CRM1 as a potential target in osteosarcoma.

Dr. O'Reilly on Ongoing Trials With PARP Inhibitors in Pancreatic Cancer

February 22nd 2020

Eileen O'Reilly, MD, Winthrop Rockefeller Endowed Chair in Medical Oncology, co-director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research, section head, Hepatopancreaticobilary and Neuroendocrine Cancers, and medical oncologist, Memorial Sloan Kettering Cancer Center, discusses

Dr. Kopetz on the Rationale and Design of the BEACON CRC Study in mCRC

February 22nd 2020

Scott Kopetz, MD, PhD, FACP, discusses the rationale and primary endpoints of the BEACON CRC study in BRAF V600E–mutant metastatic colorectal cancer.